Developing a reporting system for the surveillance of HIV drug resistance in Europe
A pilot project was carried out to investigate the feasibility of HIVDR surveillance in EU/EEA countries and to make recommendations for the design and implementation of a potential future HIVDR surveillance system at the European level.
Extensively drug-resistant gonorrhoea: risk of further dissemination within and across Europe
ECDC comment on the study 'Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018' by Eyre et al. in the Eurosurveillance edition of 7 March 2019.
Gonorrhoea: drug resistance compromises recommended treatment in Europe
Gonorrhoea is the second most commonly notified sexually transmitted infection across the EU/EEA countries with almost 500 000 reported cases between 2007 and 2016. The infection is treatable but Neisseria gonorrhoeae keep showing high levels of azithromycin resistance according to latest results of the European Gonococcal Antimicrobial Surveillance Programme.
Call for scientific collaboration to support genomic-based surveillance of Neisseria gonorrhoeae-antimicrobial resistance at EU-level
ECDC is looking to establish a scientific collaboration with an organisation which can perform whole genome sequencing (WGS) of Neisseria gonorrhoeae, carry out related data analyses, share results of the analyses with ECDC and the participants of the European Gonococcal Antimicrobial Surveillance Programme as well as visualise the results.
Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016
Day, M.J., Spiteri, G., Jacobsson, S., Woodford, N., Amato-Gauci, A.J., Cole, M.J., Unemo, M., Indra, A., Huhlescu, S., Vanden Berghe, W., Crucitti, T., Hunjak, B., Nemeth Blažić, T., Kubele, J., Zákoucká, H., Žemličková, H., Berthelsen, L., Cowan, S., Hoffmann, S., Epstein, J., Viktorova, J., Ndeikoundam, N., Goubard, A., Bercot, B., Kohl, P., Buder, S., Bremer, V., Jansen, K., Tzelepi, E., Konte, V., Balla, E., Dudás, M., Sigmundsdóttir, G., Hauksdóttir, G.S., Igoe, D., Crowley, B., Suligoi, B., Stefanelli, P., Pakarna, G., Mavcutko, V., Reichert, P., Hoffmann, P., Barbara, C., Vella, F., Melillo, J.M., Van Dam, A., Van Benthem, B., Linde, I., Kløvstad, H., Steinbakk, M., Majewski, S., Młynarczyk-Bonikowska, B., Azevedo, J., Borrego, M.-J., Pavlik, P., Truska, P., Klavs, I., Jeverica, S., Vazquez, J., Diaz, A., Abad, R., Velicko, I., Hughes, G., Templeton, K., Irvine, N.
Gonococcal antimicrobial susceptibility surveillance in Europe, 2016
The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the European Union/European Economic Area (EU/EEA) has been co-ordinated by ECDC since 2009. This surveillance is essential for detecting emerging and increasing antimicrobial resistance and making quality-assured data available to inform treatment guidelines.
Drug-resistance of gonorrhoea in the EU: persistent but stable
Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area, according to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP).
Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey
Harris, S.R., Cole, M.J., Spiteri, G., Sánchez-Busó, L., Golparian, D., Jacobsson, S., Goater, R., Abudahab, K., Yeats, C.A., Bercot, B., Borrego, M.J., Crowley, B., Stefanelli, P., Tripodo, F., Abad, R., Aanensen, D.M., Unemo, M., Azevedo, J., Balla, E., Barbara, C., Bergheim, T., Borrego, M.J., Bremer, V., Buder, S., Maikanti-Charalambous, P., Chisholm, S., Cowan, S., Crowley, B., Crucitti, T., Diez, M., Dudás, M., Eastick, K., Goubard, A., Haller, M., Hauksdóttir, G.S., Hoffmann, S., Hughes, G., Igoe, D., Jeverica, S., Klavs, I., Kløvstad, H., Kohl, P., Konte, V., Linde, I., Mavcutko, V., Melillo, J.M., Pakarna, G., Pavlik, P., Pieridou, D., La Ruche, G., Sigmundsdóttir, G., Soteriou, S., Stary, A., Stefanelli, P., Suligoi, B., Truska, P., Tzelepi, E., Unemo, M., Van Benthem, B., Van Dam, A., Vazquez, J., Velicko, I., Verbrugge, R.
ECDC: first detected cases of extensively drug-resistant gonorrhoea threaten future treatment
Within a matter of weeks, three cases of gonorrhoea that are resistant to the recommended first line antibiotic treatment have been detected in Europe and Australia. These are the first global reports of Neisseria gonorrhoeae with high-level resistance to azithromycin and ceftriaxone resistance that also show resistance to several other vital antibiotics. At a time with limited alternatives to the current dual therapy, lack of a vaccine and insufficient surveillance capacity in some regions, these cases highlight the growing threat of drug-resistance – which could lead to untreatable gonorrhoea.
Rapid Risk Assessment: Extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia
This rapid risk assessment aims to assess the risk of XDR Neisseria gonorrhoeae spreading further in the EU/EEA and provide some options for response.